Factorial study of Metoprolol Succinate TOPROL-XL (324A)
Study identifier:D4026C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase III, Multi-center, randomized, Double-blind, placebo-controlled, parallel-group factorial study of Metoprolol Succinate extended release tablets (TOPROL-XL) Hydrochlorothiazide and their combination in patients with essential hypertension.
Medical condition
High blood pressure (hypertension).
Phase
Phase 3
Healthy volunteers
No
Study drug
Metoprolol Succinate, Hydrochlorothiazide
Sex
All
Actual Enrollment
1900
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Jun 2003
Primary Completion Date: 01 Jul 2004
Study Completion Date: 01 Jul 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Metoprolol Succinate + Hydrochlorothiazide | - |
| Active Comparator: 2 Metoprolol Succinate | - |
| Active Comparator: 3 Hydrochlorothiazide | - |
Contacts
Investigators
Principal Investigator
Vasilios Papademetriou
Georgetown University Medical Center
